Aimmune Therapeutics, Inc.
They are a clinical-stage biopharmaceutical company developing treatments for potentially life-threatening food allergies.
Last Closing Price
February 22, 2018
BofA Merrill Lynch, Cantor Fitzgerald, Piper Jaffray, Credit Suisse, RBC Capital Markets
To view the prospectus for Aimmune Therapeutics, Inc., or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277